{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-21-011095","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2021-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.081808+00:00","generated_at":"2026-06-28T20:57:19.233591+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics President/CFO Michael Jebsen to depart Oct 29; CEO Giordano becomes President; interim CFO appointed","bullets":["Michael B. Jebsen (President & CFO) to depart Oct 29, 2021; receives 12 months base salary severance + prorated bonus.","CEO Christopher T. Giordano will assume additional role of President effective upon separation.","Eliot M. Lurier appointed Interim CFO via Danforth Advisors; Danforth receives $400/hour for his services.","Jebsen to provide advisory services through April 2022 at $275/hour under a 6-month consulting agreement.","Board initiates search for a permanent Chief Financial Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-21-011095","json":"https://secwatch.observer/filing/0001654954-21-011095.json","markdown":"https://secwatch.observer/filing/0001654954-21-011095.md","text":"https://secwatch.observer/filing/0001654954-21-011095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:57:19.233591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c4f37edf7","claim":"Michael B. Jebsen departed as President at TENAX THERAPEUTICS, INC..","evidence_excerpt":"Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"b35beb80f7","claim":"Christopher T. Giordano changed role as President at TENAX THERAPEUTICS, INC..","evidence_excerpt":"the Company’s current Chief Executive Officer and principal executive officer, Christopher T. Giordano, will assume the additional position of President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed additional role of"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"b484568fa2","claim":"Michael B. Jebsen departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..","evidence_excerpt":"Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"efbdbd2f7e","claim":"Eliot M. Lurier was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..","evidence_excerpt":"the Company has entered into a consulting agreement with Danforth Advisors, LLC (“Danforth”), dated October 14, 2021, providing for the engagement of Eliot M. Lurier, a consultant with Danforth, as Interim Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}